Sanofi Consumer Healthcare India Limited share price
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.Read more
HealthcareDrug Manufacturers - GeneralNSE: SANOFICONRISIN INE0UOS01011
16 Oct 2026, 3:29 PM IST₹3,548.70▼ 24.60 (0.69%)
- Market Cap₹ 8,185 Cr.
- Current Price₹ 3,548.70
- High / Low₹ 5,255 / 3,530
- Stock P/E30.7
- Book Value₹ 151
- Dividend Yield2.10 %
- ROCE77.0 %
- ROE73.10 %
- Face Value₹ 10.0
More figures (10)
- EPS (TTM)₹ 115.49
- Price / Book23.49
- OPM33.9 %
- Debt / Equity0.06
- Sales growth (2Y)27.0 %
- Profit growth (2Y)20.7 %
- Promoter holding72.5 %
- EV / EBITDA22.2
- Beta0.27
- All-time high₹ 5,895
Price chart
| Returns | 1M | 3M | 6M | YTD | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| SANOFICONR | -11.07% | -22.15% | -24.96% | -21.49% | -24.74% | — | — |
| Nifty 50 | -0.31% | -3.85% | -4.34% | -11.42% | -9.53% | +5.46% | +4.76% |
Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.
Quick take
- Sanofi Consumer Healthcare India Limited is in the Drug Manufacturers - General industry (Healthcare), with a market value of ₹8,185 crore.
- It trades at 30.7 times its last 12 months' earnings and 23.5 times book value.
- Revenue grew 27.0% a year over the last 2 years, profit 20.7% a year.
- Return on equity was 73.1% and return on capital employed 77.0% in the latest year.
- Debt was 0.06 times shareholders' equity.
- The share price is 32.5% below its 52-week high and down 24.7% over one year.
- Promoters and insiders hold about 72.5%; institutions about 18.4%.
Pros
AI- Strong return on equity: 75.9% on average over the last 3 years.
- Company is almost debt-free (debt is 0.06 times equity).
- Trades at 30.7 times earnings, below its 3-year median of 45.7.
- Promoters have raised their holding by 10.87 points over 8 quarters, to 71.27%.
- Pays a healthy dividend: about 53% of profit last year.
Cons
AI- Trades at 23.5 times its book value.
- Institutional (FII + DII) holding has fallen by 8.8 points over 8 quarters.
Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.
AI analysis
Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.
About Sanofi Consumer Healthcare India Limited
Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. The company offers products in the allergy, physical wellness, and pain care segments under Allegra, Combiflam, Avil, DePURA, Festal, and other brand names through distributors, wholesalers, government institutions and hospitals, pharmacy chains, and e-commerce platforms. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited operates as a subsidiary of Opella Healthcare Participations B.V.
- Employees
- 597
- Head office
- Mumbai
Peer comparison
HealthcareDrug Manufacturers - General
| S.No. | Company | CMP ₹ | P/E | Mar Cap ₹ Cr | Div Yld % | NP Qtr ₹ Cr | Qtr Profit Var % | Sales Qtr ₹ Cr | Qtr Sales Var % | ROCE % | ROE % | P/B | OPM % | Debt / Eq | Prom. Hold. % | Sales ₹ Cr | Sales Var 3Yrs % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | Sanofi Consumer Healthcare India | 3,548.70 | 30.7 | 8,185 | 2.10 | 69 | 13.34 | 236 | 6.70 | 77.0 | 73.1 | 23.49 | 33.9 | 0.06 | 72.52 | 878 | 27.0 |
| 2. | GlaxoSmithKline Pharmaceuticals | 2,566.10 | 40.7 | 43,471 | 2.26 | 237 | -9.77 | 938 | -3.69 | 55.4 | 49.1 | 19.17 | 32.8 | 0.01 | 75.63 | 3,808 | 5.7 |
| 3. | Rubicon Research | 1,508.60 | 86.9 | 24,973 | 0.10 | 85 | 133.91 | 534 | 49.20 | 23.6 | 19.1 | 19.32 | 20.6 | 0.24 | 69.15 | 1,731 | 36.6 |
| 4. | Pfizer | 3,814.00 | 23.7 | 17,448 | 1.97 | 204 | 6.63 | 653 | 8.31 | 22.9 | 17.2 | 4.15 | 33.6 | 0.02 | 66.96 | 2,519 | 1.3 |
| 5. | Marksans Pharma | 311.00 | 27.3 | 14,093 | 0.29 | 159 | 173.89 | 841 | 35.61 | 17.5 | 15.2 | 4.66 | 17.5 | 0.11 | 43.87 | 2,951 | 16.7 |
| 6. | Senores Pharmaceuticals | 1,318.40 | 46.4 | 6,072 | 0.00 | 31 | 55.70 | 180 | 35.95 | 15.5 | 13.4 | 5.61 | 23.0 | 0.37 | 54.93 | 614 | 159.1 |
| 7. | SMS Pharmaceuticals | 450.50 | 40.1 | 4,219 | 0.09 | 21 | 2.04 | 207 | 5.57 | 13.7 | 14.3 | 5.37 | 15.1 | 0.46 | 74.88 | 887 | 19.3 |
| 8. | Sai Parenteral's | 487.30 | 168.0 | 2,153 | 0.00 | 8 | — | 179 | — | 17.9 | 21.1 | 3.25 | 6.4 | 1.83 | 74.83 | 381 | 126.1 |
| 9. | CORONA Remedies | 2,003.90 | 61.6 | — | 0.49 | 60 | — | 422 | — | 29.0 | 27.4 | 16.41 | 18.3 | 0.22 | 77.61 | 1,403 | 16.6 |
| Median: 9 Co. | 1,508.60 | 40.7 | 11,139 | 0.29 | 69 | 13.34 | 422 | 8.31 | 22.9 | 19.1 | 5.61 | 20.6 | 0.22 | 72.52 | 1,403 | 19.3 |
Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.
Quarterly Results
Standalone figures in ₹ crore
Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.
Balance Sheet
Consolidated figures in ₹ crore, as at 31 March
| ₹ Cr | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity Capital | 2 | 23 | 23 |
| Reserves | 206 | 250 | 361 |
| Borrowings | 20 | 25 | |
| 138 | 138 | 138 | |
| Trade payables | 60 | 70 | 80 |
| Current liabilities | 130 | 131 | 128 |
| Total Liabilities | 345 | 431 | 547 |
| 2 | 28 | 35 | |
| Gross block | 5 | 32 | 43 |
| Accumulated depreciation | 3 | 4 | 8 |
| Goodwill & intangibles | 6 | 2 | 1 |
| CWIP | 1 | ||
| 343 | 403 | 512 | |
| Inventories | 97 | 41 | 62 |
| Trade receivables | 32 | 14 | 30 |
| Cash & equivalents | 2 | 327 | 375 |
| Current assets | 335 | 392 | 494 |
| Total Assets | 345 | 431 | 547 |
Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.
Cash Flows
Consolidated figures in ₹ crore, financial years ending March
| ₹ Cr | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| -0 | 439 | 175 | |
| Profit for the year | 165 | 181 | 240 |
| Working capital changes | -213 | 316 | -54 |
| Direct taxes paid | -4 | -124 | -87 |
| 2 | 8 | ||
| Fixed assets purchased | -4 | -10 | -8 |
| 2 | -116 | -135 | |
| Interest paid | -0 | -2 | |
| Dividends paid | -115 | -127 | |
| Net Cash Flow | 2 | 325 | 48 |
| Free Cash Flow | -4 | 429 | 167 |
Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.
Ratios
| Ratio | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| ROE | 79.4% | 75.3% | 73.1% |
| ROCE | 101.9% | 83.4% | 77.0% |
| Operating margin | 39.9% | 37.2% | 33.9% |
| Net margin | 30.3% | 25.3% | 27.3% |
| Debt / equity | 0.00 | 0.07 | 0.06 |
| Current ratio | 2.58 | 3.00 | 3.85 |
| Debtor days | 21 | 7 | 12 |
| Inventory days | 182 | 65 | 81 |
| Days payable | 113 | 112 | 104 |
| Cash conversion cycle | 90 | -40 | -11 |
| Working capital days | 138 | 133 | 152 |
Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.
Shareholding Pattern
Numbers in percentages · as filed with NSE each quarter
- Promoters 71.27%
- FIIs 2.60%
- DIIs 17.86%
- Public 8.27%
| % | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 71.27% | 71.27% | 71.27% | 71.27% | 71.27% |
| 5.22% | 4.42% | 4.53% | 3.24% | 2.94% | 2.83% | 2.76% | 2.60% | |
| Foreign portfolio investors (Cat. I) | 5.00% | 4.17% | 4.22% | 2.92% | 2.70% | 2.62% | 2.54% | 2.39% |
| Foreign portfolio investors (Cat. II) | 0.22% | 0.25% | 0.30% | 0.32% | 0.23% | 0.21% | 0.21% | 0.21% |
| 24.03% | 25.35% | 25.48% | 16.89% | 17.21% | 17.33% | 17.57% | 17.86% | |
| Mutual funds | 13.06% | 14.78% | 15.09% | 12.85% | 13.34% | 13.46% | 13.63% | 13.01% |
| Insurance companies | 10.75% | 10.35% | 9.78% | 4.02% | 3.87% | 3.87% | 3.94% | 4.84% |
| Alternative investment funds | 0.02% | 0.02% | 0.03% | 0.02% | ||||
| 10.36% | 9.84% | 9.59% | 8.59% | 8.58% | 8.56% | 8.40% | 8.27% | |
| Retail (up to ₹2 lakh) | 7.53% | 7.01% | 6.58% | 6.20% | 6.26% | 6.25% | 6.26% | 6.18% |
| HNIs (above ₹2 lakh) | 0.10% | |||||||
| NRIs | 1.00% | 0.99% | 0.96% | 0.94% | 0.94% | 0.95% | 0.83% | 0.81% |
| Bodies corporate | 1.29% | 1.31% | 1.42% | 0.86% | 0.87% | 0.85% | 0.79% | 0.77% |
| IEPF | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% | 0.19% |
| No. of Shareholders | 58,582 | 55,734 | 51,859 | 49,632 | 48,808 | 48,075 | 48,418 | 47,511 |
Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.
Mutual funds & institutions holding Sanofi Consumer Healthcare India
| Holder (above 1%) | Stake |
|---|---|
| Nippon India Growth Mid Cap FundMutual fund | 5.21% |
| Aditya Birla Sun Life Large Cap FundMutual fund | 3.03% |
| Hdfc Life Insurance Company LimitedInsurance | 2.12% |
| Icici Prudential Smallcap FundMutual fund · see the fund house | 1.57% |
| SBI Dividend Yield FundMutual fund | 1.47% |
| General Insurance Corporation Of IndiaInsurance | 1.30% |
| Bajaj Life Insurance LimitedInsurance | 1.06% |
As named in the shareholding pattern for Jun 2026 filed with NSE; mutual funds together hold 13.01% of the company. Shareholders below 1% are not named in the filing.
Documents
Announcements
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201812-Oct-2026
- Trading WindowSanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201528-Sep-2026
- Copy of Newspaper PublicationSanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Result for the quarter and half year ended 30th June …30-Jul-2026
- Press ReleaseSanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated July 28, 2026.28-Jul-2026
- Outcome of Board MeetingSanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026.28-Jul-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 201809-Jul-2026
- Change in AuditorsSanofi Consumer Healthcare India Limited has informed the Exchange regarding Change in Auditors of the company.29-Jun-2026
- Shareholders meetingSanofi Consumer Healthcare India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 26, 2026. Further, the company has informed the…29-Jun-2026
- Shareholders meetingSanofi Consumer Healthcare India Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on June 26, 202626-Jun-2026
- Trading WindowSanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 201526-Jun-2026
- Copy of Newspaper PublicationSanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of 3rd Annual General Meeting of the Company05-Jun-2026
- Shareholders meetingSanofi Consumer Healthcare India Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 26, 202604-Jun-2026
Annual reports
Credit ratings
None filed recently.
Concalls & investor meets
- Analysts/Institutional Investor Meet/Con. Call UpdatesSanofi Consumer Healthcare India Limited has informed the Exchange about the transcript of the Institutional Investor Meet held on Tuesday, 24th March 202627-Mar-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSanofi Consumer Healthcare India Limited has informed the Exchange about Link of Recording of Institutional Investor Meet held on Tuesday, 24th March 202626-Mar-2026
- Investor PresentationSanofi Consumer Healthcare India Limited has informed the Exchange about Investor Presentation24-Mar-2026
- Analysts/Institutional Investor Meet/Con. Call UpdatesSanofi Consumer Healthcare India Limited has informed the Exchange about Schedule of Institutional Investors Meet19-Mar-2026
Filings made by the company with NSE; documents open on NSE's website.
Key dates
- Ex-dividend date
- 19 Jun 2026
- Latest quarter
- 30 Jun 2026
- Financial year end
- 31 Dec 2025
Trade with our broking desk
Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.
Latest news
In the news
From the company (NSE)
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 12-Oct-2026
- Trading WindowSanofi Consumer Healthcare India Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015NSE filing · 28-Sep-2026
- Copy of Newspaper PublicationSanofi Consumer Healthcare India Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Result for the quarter and half year ended 30th June …NSE filing · 30-Jul-2026
- Press ReleaseSanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated July 28, 2026.NSE filing · 28-Jul-2026
- Outcome of Board MeetingSanofi Consumer Healthcare India Limited has submitted to the Exchange, the Unaudited Financial Results for the quarter and half year ended Jun 30, 2026.NSE filing · 28-Jul-2026
- Certificate under SEBI (Depositories and Participants) Regulations, 2018Sanofi Consumer Healthcare India Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018NSE filing · 09-Jul-2026
- Change in AuditorsSanofi Consumer Healthcare India Limited has informed the Exchange regarding Change in Auditors of the company.NSE filing · 29-Jun-2026
- Shareholders meetingSanofi Consumer Healthcare India Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on Jun 26, 2026. Further, the company has informed the…NSE filing · 29-Jun-2026
Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.
Questions about Sanofi Consumer Healthcare India Limited
What is the share price of Sanofi Consumer Healthcare India Limited today?
Sanofi Consumer Healthcare India Limited (SANOFICONR) last traded at ₹3,548.70 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of Sanofi Consumer Healthcare India Limited?
About ₹8,185 crore at the latest price.
What is the P/E ratio of Sanofi Consumer Healthcare India Limited?
About 30.7 times its earnings over the last 12 months.
Is Sanofi Consumer Healthcare India Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy Sanofi Consumer Healthcare India Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us
Have a question about this topic?
Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.
Experts are available Mon–Sat, 10 AM – 7 PM
Book your free wealth consultation
- 100% free
- No obligation
- Reply within 2 hours
Request received!
Thank you for trusting Plenitude Connect. An expert will contact you shortly. Please check your inbox for details.